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A B S T R A C T
Multiple sclerosis is one of the most common causes of chronic neurological disability beginning in early to
middle adult life. Multiple sclerosis is idiopathic in nature, yet increasing correlative evidence supports a
strong association between one’s genetic predisposition, the environment and the immune system.
Symptoms of multiple sclerosis have primarily been shown to result from a disruption in the integrity
of myelinated tracts within the white matter of the central nervous system. However, recent research
has also highlighted the hitherto underappreciated involvement of gray matter in multiple sclerosis
disease pathophysiology, which may be especially relevant when considering the accumulation of
irreversible damage and progressive disability.
This review aims at providing a comprehensive overview of the interplay between inﬂammation,
glial/neuronal damage and regeneration throughout the course of multiple sclerosis via the analysis of
both white and gray matter lesional pathology. Further, we describe the common pathological
mechanisms underlying both relapsing and progressive forms of multiple sclerosis, and analyze how
current (as well as future) treatments may interact and/or interfere with its pathology.
Understanding the putative mechanisms that drive disease pathogenesis will be key in helping to
develop effective therapeutic strategies to prevent, mitigate, and treat the diverse morbidities associated
with multiple sclerosis.
 2015 Elsevier Ltd. All rights reserved.
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Multiple sclerosis (MS) is an inﬂammatory demyelinating
disease of the human central nervous system (CNS) (Compston and
Coles, 2002, 2008). Recently, the International Advisory Committee
on clinical trials in MS reﬁned the two different MS phenotypes (i.e.
relapsing and progressive) on the basis of both (i) disease activity
and (ii) disease progression (Lublin et al., 2014) (Table 1).
Clinical isolated syndrome (CIS), which was not included in the
initial clinical descriptors (Lublin and Reingold, 1996), is now
recognized as the inceptive clinical presentation of a disease that
displays the characteristics of an inﬂammatory demyelinating
disorder that has yet to fulﬁll the criteria necessary to diagnose MS
(Miller et al., 2005a,b). CIS may be either active or inactive [as
deﬁned by the clinical assessment of relapse occurrence and/or
magnetic resonance imaging (MRI) activity] (Lublin et al., 2014)
and typically involves the optic nerve, brainstem/cerebellum,
spinal cord, or cerebral hemispheres (Polman et al., 2011). If CIS is
active and fulﬁlls current MS diagnostic criteria, the syndrome
transitions to relapsing-remitting (RR) MS (Polman et al., 2011).Table 1
Major characteristics of MS forms as classiﬁed by (Lublin et al., 2014).
Clinical form Disease course
Clinical isolated syndrome (CIS) Characterized by acute or sub acute o
criteria. The episode lasts more than
Between 30% and 70% of patients w
In patients with optic neuritis CIS co
In patients with brainstem syndrom
In patients with spinal cord CIS con
Age of onset between 20 and 45 yea
Female to male ratio between 2:1 a
Relapsing-remitting MS (RR MS) Characterized by relapses over days
85% of cases
Age of onset between 20 and 30 yea
Female to male ratio between 2:1 a
Progressive MS
Secondary Progressive MS (SP MS)
Primary Progressive MS (PP MS)
Characterized by progressive accum
75% of RR MS cases within 15 yea
Characterized by steady functional w
15% of cases
Later onset than RR MS (10 years)
Female to male ratio: 1:1RR MS may also be active or inactive, and is characterized by
discrete episodes of acute neurological deﬁcits and/or worsening
of a given neurological function (i.e. relapse), followed by a
complete or partial recovery (i.e. remission) (Lublin and Reingold,
1996). RR MS is the most common phenotype of MS (accounting for
85% of total cases), it displays a clear association with sex (female
to male prevalence is between 2:1 and 3:1), and develops in young
adults between the ages of 20 and 30 years (Confavreux et al.,
1980).
Progressive MS includes secondary progressive (SP) and
primary progressive (PP) MS, both of which can be either active
or inactive (as per the above) and the disease course may develop
with or without progression (measured by clinical evaluation
which is assessed at a minimum annually) (Lublin et al., 2014).
Recent data estimate that within 5 and 15 years of an initial
diagnosis of MS, 25 and 75% of patients respectively, will go on to
develop SP MS (Scalfari et al., 2014). Thus the probability of disease
progression increases in accordance with time after initial disease
onset (Scalfari et al., 2014). Unfortunately, to date there are no
clinical, imaging, immunological or pathological criteria thatnset of monophasic episode suggestive of MS, that has yet to fulﬁll the current MS
 24 h and usually affects the optic nerve, brain stem or spinal cord
ith a CIS develop MS:
nversion to MS varies between 10% and 85%
es CIS conversion to MS varies between 50% and 60%
version to MS varies between 40% and 60%
rs
nd 5:1
 to weeks, followed by complete or partial remissions over months or years
rs
nd 3:1
ulation of disability after initial relapsing course of the disease
rs of the initial diagnosis
orsening from the onset of the disease
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characterized by the progressive accumulation of disability from
the onset of the disease without identiﬁable acute relapses, affects
15% of total MS patients, does not have a clear increase in female
prevalence, and has a delayed onset as compared to RR MS (by 10
years) (Ebers, 2004).
The reasons underlying the prodigious variability of MS clinical
presentation and concordant course of disease are still under
investigation, but it has been hypothesized that the different
clinical patterns of MS may represent different phases of the same
pathologic process (Lucchinetti et al., 2000). As such, progressive
forms of MS may emerge when compensatory mechanisms of
repair fail to cope with the accumulation of the axonal and
neuronal damage induced by the inﬂammatory reaction (Franklin,
2002). Therefore, the different processes that drive demyelination
at the level of white matter (WM), as well as damage of the gray
matter (GM), should be interpreted as major determinants of
disease heterogeneity in MS patients (Lassmann et al., 2012; Trapp
and Nave, 2008). As such, a careful understanding of the role of
immune cells, glia and neurons in WM and GM lesions will be
pivotal in the quest to develop targeted treatments for each stage
of this disorder.
Herein, we provide a broad synopsis of the role of inﬂammatory
and CNS-speciﬁc cells during inﬂammation, degeneration and
regeneration in the settings of both WM and GM pathology.
Further, we describe the common pathological mechanisms
underlying both relapsing and progressive forms of MS, and
analyze how current (as well as future) treatments may interact
and/or interfere with its pathology.
1.1. Pathogenesis of multiple sclerosis
Current data support the view of MS as a complex disease
caused by a series of interactions between the environment and
one’s genetic susceptibility. The environment has been deﬁnite-
ly proven to inﬂuence MS development (Ascherio and Munger,
2007a,b). For example, smokers run an increased risk of MS
(Hedstrom et al., 2009). One of the most extensive case-control
studies (902 cases and 1855 controls) found that the odds ratio
for MS development was 1.4 for women and 1.8 for men in
active smokers as compared to sex matched non-smoking
controls (Hedstrom et al., 2009). Further, exposure to passive
smoking was found to increase the risk of developing MS
(Hedstrom et al., 2011). Interestingly, the risk of MS increases
with the cumulative dose of smoking (Hedstrom et al., 2009;
Hernan et al., 2001), and a threshold effect of cotinine (a nicotine
metabolite) in relation to MS risk has been described (Sund-
strom et al., 2008). Beyond smoking, large epidemiologic studies
have demonstrated the protective effects of vitamin D with
regard to the risk of developing MS (Munger et al., 2004). In line
with this ﬁnding, healthy controls have higher serum levels of
25(OH)D3 and 1,25(OH)2D3 (the active forms of vitamin D) than
RR MS patients (Correale et al., 2009), and levels in patients
suffering a relapse are lower than during remission (Correale
et al., 2009). Of note, low serum vitamin D levels have also been
associated with an increased risk of conversion to MS in patients
with CIS (Ascherio et al., 2014; Martinelli et al., 2014). The
molecular underpinnings of such ﬁndings may be related to
induction of CD4+ factor forkhead box P3 (FOXP3+) regulatory T
cells by 1,25(OH)2D3 via the rendering of tolerogenic dendritic
cells (Penna et al., 2005). Other relevant mechanisms may
include the reported decrease in proliferation of both freshly
isolated CD4+ T cells and myelin basic protein (MBP)-speciﬁc T
cells by 1,25(OH)2D3, a reduction in the number of IL-6 and
IL-17 secreting, and/or an increase in IL-10 producing T cells
(Correale et al., 2009).MS affects more women than men (Confavreux et al., 1980), it is
associated with other autoimmune diseases (e.g. type1 diabetes
and autoimmune thyroiditis) and has a clear genetic predisposition
(Compston and Coles, 2002). Speciﬁcally, the genetic susceptibility
of MS has been associated with variations of the class II Major
Histocompatibility Complex (MHC) and non-MHC variants (Inter-
national Multiple Sclerosis Genetics et al., 2011), which are
involved in T-cell activation/regulation (Compston and Coles,
2002).
Given the complex interplay between the environment and
genetics, one of the key questions in MS research that remains
unanswered is whether the inﬂammatory reaction that occurs
within the CNS is initiated by an autoimmune attack (triggered by
an as of yet unidentiﬁed environmental factor in the periphery),
and/or represents a response to degenerative processes that are
intrinsic to the CNS (Friese and Fugger, 2007).
Two major mechanisms have come to prominence in an effort
to identify the most likely triggers of MS and are as follows:
molecular mimicry between self-antigens and infectious agents and
bystander activation of autoreactive immune T cells (Libbey et al.,
2007; Sospedra and Martin, 2005).
Molecular mimicry is a phenomenon that occurs when self-
antigens and infectious agents share similar peptide sequences
and/or structural motifs (Fujinami and Oldstone, 1985;
Wucherpfennig and Strominger, 1995). As such, when the
immune system is challenged by a relevant infection, an immune
attack against epitopes shared between self and non-self is
initiated. Bystander activation, as a potential mechanism leading
to the onset of MS, instead requires the primary activation of
tissue-resident antigen presenting cells (APCs) within the CNS
(Sospedra and Martin, 2005). Once activated, these APCs allow T
cells to begin an autoimmune response against CNS epitopes
(Munz et al., 2009).
The most probable explanation is that these two mechanisms
act jointly and in so doing together inﬂuence MS pathogenesis.
The initial activation of innate immune cells within the CNS may
be secondary to intrinsic (CNS speciﬁc) or extrinsic (e.g. virally
mediated) damage. Such activation would subsequently lead to
the leakage of CNS speciﬁc proteins from the blood–brain barrier
(BBB) and their accumulation in draining lymph nodes (Stern
et al., 2014). These mechanisms would in turn lead to the
recruitment within the CNS of lymphocytes (from the periphery)
that have been pre-primed with environmental triggers. Upon
entering the CNS, lymphocytes would then induce a massive
secretion of pro-inﬂammatory cytokines by microglia/macro-
phages, which would induce the destruction of CNS-tissue and the
release of additional CNS antigens (i.e. epitope spreading)
(McMahon et al., 2005; Owens et al., 2011; Sospedra and Martin,
2005).
While the precise targets of this autoimmune response have yet
to be fully elucidated, a series of relevant self-antigens have been
identiﬁed over the past years, such as myelin oligodendrocyte
glycoprotein (MOG), proteolipid protein (PLP), myelin associated
glycoprotein (MAG), myelin basic protein (MBP), 20,30-cyclic-
nucleotide 30-phosphodiesterase (CNPase), aB crystalline, and
S100b protein (McCarthy et al., 2012; Sospedra and Martin, 2005).
Concordantly, the most widely excepted experimental animal
model of MS (experimental autoimmune encephalomyelitis or
EAE) is induced using myelin antigens such as MBP, PLP, MAG, and
MOG (Petry et al., 2000; Steinman, 1995). One of the best-
characterized self-antigens, MBP (the major constituent of myelin
in the CNS), shares both MHC class II and T cell receptor-binding
motifs with several viruses [e.g. herpes viruses and Epstein-Barr
(EBV)]. In particular, EBV, which has been detected in both MS
lesions (Peferoen et al., 2010; Sargsyan et al., 2010; Seraﬁni et al.,
2007; Willis et al., 2009) and in serum-epidemiological studies,
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Munger, 2007a). It is known that primary EBV infection (EBV
seroconversion) increases the risk of developing MS (Levin et al.,
2010) and this risk is higher with an increasing titer of antibodies
against the EBV nuclear antigen (Munger et al., 2011). Further,
Seraﬁni et al. have found meningeal B cells within lymphoid
follicular structures in SP MS patients to be positive for EBV small
nuclear mRNA and immunoreactive for the EBV nuclear antigen,
latency membrane protein-1, and the BFRF1 lytic protein (Seraﬁni
et al., 2007). However, this data remains controversial, as
subsequent work has failed to detect EBV within the meninges
in the vast majority of MS patients (Willis et al., 2009).
The abovementioned, together with the putative role of
endogenous retroviruses in MS pathogenesis (Nissen et al.,
2013), does suggest that viruses might play a prominent role in
inducing the initial activation of innate immune cells (Lang et al.,
2002; Wucherpfennig and Strominger, 1995).
2. Inﬂammation
2.1. White matter lesions
WM lesions in MS were ﬁrst described by Charcot over
165 years ago in the course of post-mortem studies, as multiple
focal sclerotic plaques scattered throughout the WM of the brain
and the spinal cord (Charcot, 1848). Both early neuropathological
reports and contemporary MRI ﬁndings have clearly demonstrated
that WM lesions have a tendency to involve the optic nerve and a
propensity to locate to the periventricular WM, juxtacortical
border and to the cerebellum/brainstem of MS patients (Charcot,
1848; Fazekas et al., 1999). WM brain lesions are commonly round
or ovoid in nature and range from a few millimeters to more than
one centimeter in size. WM abnormalities are also found in the
spinal cord of 90% of MS patients (Nijeholt et al., 1998). These
spinal cord lesions are typical located in the cervical region and are
aligned with the long axis of the cord. Further, they usually extend
less than two vertebral segments in length and typically involve
less than half of the axial cord (Lycklama et al., 2003).
MRI is currently the most sensitive technique for detecting WM
lesions in vivo (Montalban et al., 2010) and its role in the diagnosis
of clinical MS is paramount (Barkhof et al., 1997; Polman et al.,
2011). Nonetheless, the pathological examination of MS lesions
can still provide valuable insights into the progression of the
different types and/or stages of the disease process. The initial
pathological classiﬁcation of WM lesional activity was based on the
presence of MHC class II receptors, adhesion molecules, cytokines,
and the activation state of inﬁltrating lymphocytes and macro-
phages (Adams et al., 1989). However, this classiﬁcation system
was inadequate, as it could not discriminate between inﬂamma-
tory and demyelinating activity within the lesions. To overcome
this limitation, a new categorization of active WM lesions was put
forth to combine the state of macrophage activation and
concomitant myelin degradation (Bruck et al., 1996). Active MS
demyelinating lesions are now segregated into four distinct
patterns that arise from distinct pathophysiological mechanisms
(please refer to the demyelination section for further details on the
pathogenesis of the different lesional patterns in MS) (Lucchinetti
et al., 2000).
Pattern I lesions (Fig. 1A) are found in 10% of total MS patients,
with a higher incidence in those suffering from acute MS (i.e.
<1 year of disease history), and are characterized by sharply
demarcated lesional edges with perivascular inﬁltrating T cells and
active demyelination with activated microglia and myelin-laden
macrophages (Lucchinetti et al., 2000). Pattern II lesions (Fig. 1B)
are found in 55% of total MS patients and are characterized by a
massive inﬁltration of T cells and myelin-laden macrophages withprominent deposition of immunoglobulins (Ig)s, mainly IgG, and
complement (i.e. C9neo) antigen at sites of active myelin
destruction (Lucchinetti et al., 2000). Pattern III lesions (Fig. 1C)
are found in 30% of total MS patients, and are characterized by ill-
deﬁned borders, with dying oligodendrocytes and inﬂamed vessels
surrounded by a rim of spared myelin with an early preferential
loss of MAG and CNPase immunoreactivity (Lucchinetti et al.,
2000). Pattern IV lesions are quite rare (Fig. 1D), they are found
only in PP MS patients (5% of the cases), and show inﬁltrating
T cells and activated microglia/macrophages with extensive non-
apoptotic oligodendrocyte degeneration in the peri-lesional WM
adjacent to the active lesion (Lucchinetti et al., 2000).
It has recently emerged that patients presenting with one
lesional pattern tend to conserve that pattern throughout the
course of their disease (i.e. intra-individual homogeneity) (Metz
et al., 2014). This concept has been challenged by other authors,
who have described an intra-individual temporal heterogeneity of
lesions (i.e. a progression from heterogeneity to homogeneity of
lesional subtype over the course of the disease) (Breij et al., 2008).
Despite such controversy, it is clear that during the disease course,
the four active lesional patterns become fully demyelinated and
ultimately convert to a common inactive morphology. Under-
standing how these different inﬂammatory lesional patterns
evolve during early vs. chronic phases of the disease will shed
light on the mechanisms that drive MS activity and progression.
2.1.1. Relapsing remitting MS
Orchestrated lymphocytic activation is the major driver of WM
damage and guides the evolution of WM lesions. The initial phase
of the inﬂammatory response in MS is characterized by peripheral
activation of T cells with encephalitogenic potential (i.e. T cells that
recognize speciﬁc molecules of the CNS) (Wekerle et al., 1987).
Activated T cells up-regulate the expression of a4-integrins on
their surface, which mediate a transient binding with vascular cell
adhesion molecules (VCAMs) expressed on endothelial cells
(Engelhardt and Ransohoff, 2012). Particularly CD49, the a4
subunit of very late antigen (VLA)-4 receptor, is involved in the
migration of immune cells across the BBB by interacting with
endothelial VCAM-1. After this initial interaction, activation of
G-coupled protein signaling leads to an increase in the afﬁnity of
a4 and b2 integrins for VCAMs, thereby allowing the full arrest of T
cells on the vascular wall. Integrin-mediated adhesion and
polarization eventually promotes T cell crawling on the endothe-
lium, which is predominantly regulated by high afﬁnity leukocyte
function-associated antigen (LFA)-1 and its endothelial ligands,
intercellular adhesion molecules (ICAMs)-1/2. T cells then cross
the endothelial layer via diapedesis (Engelhardt and Ransohoff,
2012), the endothelial basement membrane via a6b1 integrin-
dependent activation (Sixt et al., 2001; Wu et al., 2009), and the glia
limitants via the secretion of matrix metalloproteinases (MMP)
(i.e. MMP-2 and MMP-9) (Agrawal et al., 2006; Toft-Hansen et al.,
2004). Upon CNS entry, encephalitogenic T cells start to release
pro-inﬂammatory cytokines, [e.g. interferon (IFN)-g or osteopon-
tin], which activate microglia (Chabas et al., 2001).
Activated microglia/macrophages in turn secrete chemokines
of the CXC family [interleukin (IL)-8, CXC-ligand-10)] and of the
CC family (macrophages inﬂammatory protein-1a/1b, monocyte
chemoattractant protein-1, CC-ligand-5), which contribute to the
intracerebral recruitment of T cells, additional macrophages, and
dendritic cells (Aloisi, 2001). Local and inﬁltrating activated APCs
present myelin antigens associated with MHC class II and express
co-stimulatory molecules (e.g. CD40 and B7 glycoproteins)
capable of further activating inﬁltrating lymphocytes (Sanders
and De Keyser, 2007). Pro-inﬂammatory cytokines [e.g. tumor
necrosis factor (TNF)-a and IFN-g], reactive oxygen species, and
proteolytic/lipolytic enzymes are also released by activated
Fig. 1. Active white matter lesions in multiple sclerosis can be grouped in pattern I (A), II (B), III (C) and IV (D). Abbreviations: Igs: immunoglobulins; MAG: myelin-associated
glycoprotein; CNPase: 20 ,30-Cyclic-nucleotide 30-phosphodiesterase.
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of T cells (McMahon et al., 2005; Greter et al., 2005; Heppner et al.,
2005).
Different subtypes of T cells (e.g. CD8+ and CD4+) participate in
the autoimmune response and in so doing play vastly different
roles with regard to the ﬁnal pathological outcome. CD8+ cytotoxic
T lymphocytes are known to be major constituents of inﬂamed
plaques and play a key role in axonal transection and oligoden-
drocyte death (Johnson et al., 2007). Moreover, data from
preclinical studies show that CD8+ cytotoxic T cells may increase
the vascular permeability of the BBB via a perforin-dependent
mechanism (Johnson et al., 2005).
The role of CD8+ T cells notwithstanding, MS has traditionally
been viewed as a CD4+ T cell-mediated autoimmune disease. Amongeffector CD4+ T cells, T helper (Th) cells have divergent roles upon
their differentiation into either a pro-inﬂammatory (Th1) or anti-
inﬂammatory (Th2) phenotype. Th1 polarization is promoted by
IL-12 and characterized by the secretion of IFN-g, TNF-a, TNF-b, and
IL-2 (Abbas et al., 1996; Murphy and Reiner, 2002). The Th2
phenotype is instead promoted by IL-4 and characterized by the
secretion of anti-inﬂammatory cytokines, which include IL-3, IL-4,
IL-5, IL-6, IL-10 and IL-13 and transforming growth factor (TGF)-b
(Abbas et al., 1996; Murphy and Reiner, 2002). The identiﬁcation of a
distinct CD4+ cell subpopulation that produces IL-17 (designated as
Th17 cells) led to a revision of the abovementioned paradigm (i.e.
Th1/Th2 axis) in MS (Sung et al., 2008). The Th17 cell phenotype is
dependent on several factors (IL-1, IL-6, IL-21, IL-23, TGF-b), among
which IL-23 is essential in driving Th17 lymphocyte expansion.
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IL-17F, IL-22 (which are major determinants of BBB derangement in
MS) as well as IL-21, IL-9 and TNF-a (Sung et al., 2008).
The equilibrium between Th cells and other T cell subsets
[particularly natural and adaptive T regulatory (Treg) cells)] within
the sites of inﬂammation is critical in determining the evolution of
CNS pathology (Sakaguchi et al., 2006). Natural Treg cells express
CD25 and the transcription of FOXP3, and are essential for
controlling autoimmunity by mediating immunological tolerance
to self-antigens (Sakaguchi et al., 2006). Adaptive Treg cells,
including Treg-1, Th3 and various subsets of CD8+ Treg cells,
instead exert their immune suppressive functions primarily via
IL-10 (Treg-1) and TGF-b (Th3) secretion. Clearly, both natural and
adaptive Treg cells play a fundamental role in maintaining immune
homeostasis, and profoundly shape autoimmune inﬂammation
during MS (Sakaguchi et al., 2006). In line with this, clinical
evidence supports the contention that much of the initial
underlying disease pathogenesis may be attributed to the reduced
functional capacity of circulating regulatory T-cells. Coordinate
with this, Viglietta et al. reported a signiﬁcant decrease in the
effector function of CD4+CD25high regulatory T cells from
the peripheral blood of patients with MS as compared to healthy
controls. Differences were also apparent in single cell cloning
experiments in which the cloning frequency of CD4+CD25high
T cells was signiﬁcantly reduced in patients as compared with
normal controls (Viglietta et al., 2004).
Several lines of evidence support a role for B cells and
antibodies in MS pathogenesis (Hauser et al., 2008), challenging
the concept that MS is a disease driven solely by activated T cells
(Owens et al., 2006) (please refer to the demyelination section for
further details). Increased levels of Igs in the cerebrospinal ﬂuid
(CSF) of MS patients, which appear as oligoclonal bands after
immunoelectrophoresis, indeed represent one of the hallmarks of
MS (Link and Huang, 2006). B cells exert multiple pro-inﬂamma-
tory and regulatory functions in MS pathology: (i) they differenti-
ate into plasma cells and secrete Igs which can process antigen for
T cell activation and/or for macrophage phagocytosis; (ii) they act
as APCs for auto-reactive T cells; and (iii) they secrete both
pro-inﬂammatory (e.g. IL-6, IL-12, TNF), and anti-inﬂammatory
(e.g. IL-10) cytokines (Krumbholz et al., 2012).
2.1.2. Pre-active lesions
The observation of clusters of activated microglia (HLA-DR+,
CD68+ and CD45high) within the CNS of MS patients in the absence
of BBB derangement, demyelination, axonal loss, and T cell
activation, has challenged previous theories on MS pathogenesis
(Van der Valk and Amor, 2009). These pre-active lesions are not
associated with a speciﬁc MS sub-type [being that they are
typically found in similar number and size in RR, as well as in SP
and PP MS patients (De Groot et al., 2001)], and can be identiﬁed as
part of the normal appearing WM (Filippi et al., 2012).
The lack of BBB breakdown described in pre-active lesions lends
support to the hypothesis that MS may in part be driven by an
innate immune response within the CNS itself, independent of
direct/causative peripheral immune factors (van Noort et al., 2011).
As such, microglia activation may be considered the initiator of
pathologic alterations within the CNS. The BBB would then be
secondarily affected by factors released by activated microglia (e.g.
IL-17, TNF-a) and/or directly by factors that trigger the initial
microglial response (van Noort et al., 2011). However, it is prudent
to note that these lesions are not necessarily synonymous with
early disease activity, but may rather be a consequence of a diffuse,
persistent activation of innate immune cells.
The ultimate fate of pre-active lesions seems to be regulated
by both neurodegenerative and neuroprotective factors released
by activated microglia/macrophages. On one side, microglia/macrophage activation is associated with the release of pro-
inﬂammatory cytokines (e.g. TNF-a and IFN-g), reactive oxygen
species, proteinases and various complement proteins (Mayo et al.,
2012). On the other side, microglia/macrophages may play a
beneﬁcial, anti-inﬂammatory role by secreting nerve growth
factor, brain-derived neurotrophic factor, insulin-like growth
factor-1, as well as an variety of anti-inﬂammatory cytokines
(e.g. IL-10 and TGF-b) (Mayo et al., 2012). It is known that the
function of macrophages may be related to their capacity to
assume distinct activation states, which are roughly divided into a
pro-inﬂammatory (classically-activated) M1-like state (associated
with host defense, cytotoxicity, secretion of pro-inﬂammatory
cytokines, proteases and reactive oxygen and nitrogen species) and
an anti-inﬂammatory (alternatively-activated) M2-like state
(associated with an increase in angiogenic capacity, and the
secretion of anti-inﬂammatory cytokines, growth and neuro-
trophic factors) (Biswas and Mantovani, 2010; Miron and Franklin,
2014). It is interesting to note that M2-polarized macrophages
exist within pre-active lesions where they help to maintain a state
in which tissue damage remains reversible, thus representing a
novel and attractive future therapeutic target (Van der Valk and
Amor, 2009; van Noort et al., 2011).
2.1.3. Progressive MS
As previously stated, the different inﬂammatory MS lesional
patterns ultimately converge into a morphologically demarcated
hypo-cellular area that contains only a minimal amount of
macrophages characterized by periodic acid Schiff degradation
products and/or empty vacuoles (Lucchinetti et al., 1999). Due to a
longer course of disease, these inactive lesions have a higher
prevalence in progressive MS, compared to RR MS patients (Prineas
et al., 2001). Interestingly, within progressive MS subtypes,
inactive lesions display different characteristics, with an increased
number of incompletely remyelinated axons found in SP MS
compared to PP MS patients (Bramow et al., 2010). This difference
may suggest that the mechanisms affecting CNS repair in SP MS are
different from those that occur in PP MS and may depend on the
presence of an intrinsic block in remyelination (please refer to the
remyelination section for further details), and/or the persistence of
an (inhibitory) inﬂammatory milieu (Patrikios et al., 2006).
In support of this latter hypothesis, a slowly expanding
demyelination (from the lesional core) is a typical ﬁnding of many
inactive lesions in SP MS. These slowly expanding lesions are
characterized by a hypo-cellular center (morphologically deﬁned
by a complete loss of microglia/macrophages and oligodendro-
cytes), a dense astrocytic scar, and an external border of activated
microglia (Lassmann, 2011). Slowly expanding lesions are probably
due to the evolution of pre-existing active lesions, in which minor
demyelinating activity is still present despite the absence of major
BBB damage (Frischer et al., 2009; Prineas et al., 2001). However, the
profound loss of microglia/macrophages within the center of these
lesions, suggests that the mechanism of demyelination may be
somewhat different from that of active lesions. As such, the modest
perivascular cufﬁng and the impaired phagocytosis of myelin (i.e.
myelin fragments found on the surface of microglia/macrophages)
point towards an inefﬁcient clearance of myelin debris, which is in
part responsible for the failure of remyelination and perpetuation of
the local inﬂammatory response (Prineas et al., 2001).
2.2. Gray matter lesions
Involvement of the GM in MS was initially described in the late
1800s by Charcot, who was the ﬁrst to point out the existence of
demyelinated lesions within the GM of brain convolutions (JM,
1877). However, due to the inherent difﬁculties in the visualization
of GM lesions using traditional histological methods, his ﬁndings
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within a cohort of MS autopsies was performed by Brownell and
Hughes in 1962 (Brownell and Hughes, 1962). These authors found
that 26% of the total number of MS lesions were actually located
in the cortical GM and/or at the border with the WM. The extent of
GM involvement in MS has since been conﬁrmed using myelin
speciﬁc protein immunohistochemistry, and today the critical
importance of GM pathology in MS is well accepted (Bo et al.,
2003a; Peterson et al., 2001). Advanced imaging techniques have
ﬁrmly established that cortical demyelination is in fact a common
feature of MS, independent from the clinical course of the disease,
and may even be equal and/or in excess of WM lesional load
(Filippi and Rocca, 2012; Geurts, 2012). Clearly, the study of the
pathophysiology of GM involvement in MS is of pivotal importance
if one seeks to understand the origins of disease, response to
treatment and/or accurately predict patient prognosis.
Early descriptions of cortical lesions in MS were obtained from
patients with progressive MS. This selection bias led the scientiﬁc
community to believe that GM lesions differed signiﬁcantly from
those involving the WM, which had been primarily characterized
by substantial inﬁltration of peripheral leukocytes and BBB
derangement (Bo et al., 2003a). As compared to WM lesions,
cortical lesions were then assumed to be less inﬂammatory and
contain fewer microglia/macrophages (Peterson et al., 2001) and
T cells (Bo et al., 2003a). Given this putative absence of overt
inﬂammation within GM lesions, the pathological classiﬁcations of
cortical lesions in MS are still based on their position within the
parenchyma, rather than the pertinent characteristics of the
inﬂammatory inﬁltrate.
The ﬁrst classiﬁcation of GM lesions, identiﬁed seven types
which depended on their relationship to the cortical veins (Kidd
et al., 1999). Due to its complexity, this initial classiﬁcation system
was replaced by a simpler categorization of GM lesions, which
currently identiﬁes four main types according to their location
within the cortical GM (Calabrese et al., 2009; Peterson et al., 2001).
Type I lesions, also called leukocortical lesions, are areas of
demyelination that project radially from small vessels, and involve
both the deeper layers of the GM and the contiguous GM/WM
junction. These lesions are the second most prevalent in progressive
MS (representing 38% of total lesions) and are characterized by a
substantial cell (both glial and neuronal)/synaptic loss (Wegner
et al., 2006). Type II lesions, also called intracortical lesions, are small,
perivascular areas of demyelination that are conﬁned within the
cortex and spare both the superﬁcial cortex as well as the underlying
WM. These lesions are relatively less frequent in progressive MS
(representing 18% of total lesions) than other lesion types (Wegner
et al., 2006). Type III lesions extend from the pial surface into the ﬁrst
cortical layers (with the majority reaching layers 3 or 4) and can
transverse multiple/adjacent gyri. Finally, type IV lesions extend
from the pial surface and encompass the entire width of the cortex,
yet do not involve the subcortical WM. Given their similarity, type III
and IV lesions are called subpial lesions and contribute signiﬁcantly
to the total lesion load in MS (44% of GM lesions) (Wegner et al.,
2006). Subpial lesions can also be quite extensive, affect more than
60% of the cortical ribbon within the brain (Kutzelnigg et al., 2005),
and extend to deep neuronal structures (Geurts et al., 2007).
Despite the validity of the described classiﬁcation system for
patients with chronic MS, recent research on brain biopsies
obtained from patients with early MS have revealed that GM
lesions do in fact show profound lymphocytic inﬁltration,
increased BBB damage and meningeal inﬂammation at their very
onset (Lucchinetti et al., 2011).
2.2.1. Relapsing remitting MS
Cortical demyelination and BBB damage occur early in the
disease course of MS and often precede the appearance of classicWM plaques (Calabrese and Gallo, 2009; Popescu et al., 2011) [it
has been noted that 37% of patients with a CIS show the presence of
GM pathology (Calabrese et al., 2007)]. Cortical lesions are more
numerous – and cortical atrophy is more pronounced – in certain
subgroups of RR MS patients (Popescu and Lucchinetti, 2012). For
example, RR MS patients with cognitive deﬁcits have more GM
lesions than RR MS patients without cognitive impairment
(Calabrese et al., 2009). Similarly, a more severe – and rapidly
evolving – cortical lesion load is found in RR MS patients with
epilepsy (Calabrese et al., 2012a).
Throughout the disease course, GM lesions represent an
important aspect of MS pathology. A longitudinal MRI study of
64 MS cases (38 of whom were classiﬁed as RR MS) documented
periodic peaks of increased diffusion coefﬁcients in the normal
appearing cortex, perhaps reﬂecting episodes of focal and diffuse
cortical damage caused by local inﬂammatory reactions (Vrenken
et al., 2006). The majorities of cortical lesions in early MS are highly
inﬂammatory in nature and show an accumulation of myelin-
laden macrophages, T cell and B cell perivenular inﬁltrates, as
described for active WM lesions (Lucchinetti et al., 2011). In
representative tissues from early MS cases, 82% of lesions showed
extensive T cell inﬁltrates, while 41% showed macrophage-
associated demyelination (Lucchinetti et al., 2000, 2011). Interest-
ingly, lymphocytes, microglia/macrophages were predominantly
seen in apposition to pyknotic neurons and neurites, thus
suggesting a direct role in the ﬁnal stages neuronal damage/death
(Popescu and Lucchinetti, 2012).
2.2.2. Progressive MS
Several authors have pointed out that cortical demyelination is
one of the main pathologic drivers of disease progression in MS. A
ﬁve year longitudinal study on more than 300 MS patients has
shown that GM and WM changes occur partly independently, and
that GM damage is strongly associated with both physical and
cognitive disability progression, more so than WM lesion load
(Calabrese et al., 2012b). As such, GM lesions may provide a
pathological correlate for the cognitive and executive dysfunction
that commonly arises in the vast majority of MS patients during
disease progression (Chiaravalloti and DeLuca, 2008).
Cortical demyelination in patients with progressive MS has
mainly been detected in the cingulate gyrus, and the frontal,
temporal and insular cortices (Popescu and Lucchinetti, 2012).
Another brain area that displays extensive cortical demyelination
is the cerebellum, where 39% of the cortex was found to be
demyelinated in SP MS patients and 37% in PP MS patients
(Kutzelnigg et al., 2007). Among the deeper brain structures, the
hippocampus exhibits prominent demyelination (in 78% of chronic
MS) (Geurts et al., 2007) and deﬁcits in memory and visuospatial
learning correlate with regional hippocampal atrophy (Longoni
et al., 2013). Demyelination has been also reported in other GM
areas including the basal ganglia (e.g. thalamus) and the spinal GM
(Geurts et al., 2009).
Activated microglial cells represent the vast majority of
phagocytic cells in cortical lesions of patients with chronic
progressive MS, and are found in close association with degen-
erating neurites and neuronal cell bodies (Peterson et al., 2001).
Among the different types of GM lesions, type II lesions are
characterized by the lack of lymphocytic and macrophagic
inﬂammatory inﬁltrates, complement deposition and BBB break-
down. Conversely, type I lesions are more inﬂammatory, but still
less than classically activated WM lesions (Bo et al., 2003a,b;
Calabrese et al., 2013; Popescu and Lucchinetti, 2012). GM damage
appears to play a pivotal role in determining the clinical course of
MS, and the combined assessment of both WM and GM
involvement may prove useful in predicting disease progression/
treatment responses moving forward.
Fig. 2. Gray matter lesions in multiple sclerosis. Meningeal inﬁltrates are characterized by the presence of lymphocytes intermingled with stromal cells and macrophages. The
core of these lymphoid organs consists of B cells whose maturation process is supported by FDCs, while the cortex of the tertiary lymphoid organ consists of T cells and
macrophages. Meningeal inﬁltrates (especially in deep cortical sulci) are associated with extensive microglia activation in the underlying cortex and gray matter damage. The
most likely justiﬁcation for the association of microglial activation in the cortex and meningeal inﬂammation is a soluble factor produced within the meningeal inﬂammatory
inﬁltrate and accumulated in the cerebrospinal ﬂuid. Abbreviations: FDCs: follicular dendritic cells.
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A salient feature of cortical demyelination in early and late MS is
its topographic link to meningeal inﬂammation (Fig. 2). In early MS
a moderate-to-severe meningeal inﬂammation is associated with
cortical demyelination in a statistically signiﬁcant manner (90%
probability), especially for subpial plaques, when compared with
type I and II lesions (Lucchinetti et al., 2011). Interestingly, both
diffuse meningeal inﬂammation and focal perivascular meningeal
inﬁltration of T cells and B cells were shown to be signiﬁcantly
associated with cortical lesions in early MS. In late-stage progres-
sive MS meningeal inﬂammatory inﬁltrates have been extensively
identiﬁed and topographically related to the subpial demyelination
of the underlying cortex (Kutzelnigg et al., 2005).
Although GM lesions display a remarkable difference between
the early and late phases of MS, the shared hallmark of meningeal
inﬂammation does suggest a common underlying pathological
process. Major insights into this phenomenon came from the
pathological analysis of progressive MS patients, which showed a
prevailing population of microglial cells within areas of cortical
demyelination close to meningeal inﬂammatory inﬁltrates, thus
suggesting the existence of an inﬂammatory process within the
GM that is driven by the meningeal inﬁltrates (Howell et al., 2011).In line with the aforesaid, consistent in vivo imaging of microglia
activation by PK11195 positron emission tomography (PET)
binding has revealed extensive regional activation of microglia
in the MS cortex of both RR MS (40% of cases) and SP MS patients
(75% of cases) (Politis et al., 2012).
The putative mechanisms governing the interactions between
inﬂammatory cells accumulating in the GM and in the meningeal
inﬁltrates have yet to be fully elucidated. However, the most likely
justiﬁcation for the association of GM damage and meningeal
inﬂammation is that soluble factors produced within the
meningeal inﬂammatory inﬁltrates diffuse into the adjacent
cortex, and induce cortical damage directly and/or through
microglia activation (Choi et al., 2012). Interestingly, subpial
demyelination preferentially involves the deep cortical sulci, thus
suggesting that it may be induced by stagnant mediators that are
transported by the physiological ﬂow of the CSF (Popescu and
Lucchinetti, 2012). There is uncertainty with regard to which cell
type may be the source of these reputed mediators. The
observation that B cells, plasma cells and myelin-speciﬁc
antibodies are present in MS lesions - and that Igs levels are
increased in the CSF of MS patients - does provide supporting
evidence for a role of B cells/humoral immunity in MS pathogene-
sis (Presslauer et al., 2008). It is tempting to speculate that a B cell
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GM damage in MS (Torkildsen et al., 2010), even if in cortical
lesions from patients with progressive MS evidence for antibody
and complement-mediated demyelination is currently lacking
(Brink et al., 2005). Nonetheless, it is reasonable to consider that
early meningeal inﬂammation in MS, accompanied by the
secretion of disease mediators in the subarachnoid space, could
target inﬂammatory cells within the GM and in so doing drive
disease progression.
Major differences in the pathology of meningeal inﬁltrates
between SP MS and PP MS patients have been described, and only
the correct understanding of their biology can guide future
treatments. In SP MS patients, meningeal inﬁltrates are character-
ized by the presence of organized ectopic lymphoid-like follicles
(tertiary lymphoid structure), which are found in close relation with
GM lesions (Howell et al., 2011). Ectopic B cell follicle-like
structures are found, with variable frequency, in 40% of SP MS
patients and are distributed throughout the forebrain (frequently
located in the temporal, cingulate, insula and frontal cortex). These
tertiary lymphoid structures within the CNS resemble secondary
lymphoid organs and contain proliferating B and follicular
dendritic cells (FDCs) (Aloisi and Pujol-Borrell, 2006). Importantly,
the presence of B cell follicle-like structures is associated with an
accompanying quantitative increase in diffuse meningeal inﬂam-
mation that correlates with the degree of microglial activation and
GM cortical demyelination (Howell et al., 2011). The presence of
meningeal follicles is also associated with the early onset of severe
cortical pathology and subsequent disease progression in many SP
MS patients (Magliozzi et al., 2007).
In PP MS, substantial clusters of T cells and B cells characterize
meningeal inﬂammatory inﬁltrates. However, no proliferating
CD20+ B cells or FDCs – which would be suggestive of a tertiary
lymphoid-like structure – can be found (Choi et al., 2012). Despite
the fact that these cells do not display an organization typical of B
cell follicle-like structures, meningeal inﬁltrates do play a critical
role in PP MS as well. In fact, PP MS patients with extensive
meningeal immune cell inﬁltration exhibit a more extensive
microglial activation, demyelination and neurite loss, which is
coupled with a more severe clinical course (e.g. younger age at
death) (Choi et al., 2012).
It is becoming increasingly clear that inﬂammation in the
progressive stage of MS is maintained within the CNS despite the
reconstitution of the BBB (Lassmann, 2013), and therefore a
focused targeting of the crosstalk between lymph follicle-like
aggregates within the meninges and the cortical microglia can/will
lead to successful treatments, which will hopefully preclude
progressive neurodegeneration (Lassmann, 2013).
3. Glial and neuronal damage
3.1. Demyelination
Oligodendrocytes are specialized glial cells that provide
support and insulation to neurons in the CNS by wrapping lipid-
rich concentric membranes (myelin sheaths) on axons via protein-
protein interactions (Hauser and Oksenberg, 2006). Major myelin
proteins include proteolipid protein (50% of the total), a group of
myelin basic protein isoforms (30% of the total), and minor
proteins such as MOG, CNPase, MAG, that as a whole represent less
than 1% of the total (Cuzner and Norton, 1996). Beyond trophic
support, myelin sheaths alter the electrical properties of the axon,
creating regions of high resistance and low capacitance, thereby
facilitating rapid saltatory propagation of nerve impulses between
regions of the exposed axolemma (nodes of Ranvier) (Irvine and
Blakemore, 2008; Waxman and Ritchie, 1993). When myelin
or myelin forming cells are damaged by the autoimmuneinﬂammatory response, both the support and the insulation of
axons is compromised, thus leading to deﬁcits in neuronal function
that can be reversible (i.e. conduction block) or permanent.
Distinct mechanisms that drive the initial demyelination have
been described within the different lesional patterns of MS. While
in lesional patterns I and II demyelination is trigged primarily via
the damage of myelin sheaths, in lesional patterns III and IV the
death of the oligodendrocytes themselves represents the key
driver of disease pathogenesis (Lucchinetti et al., 2000).
Direct damage of myelin sheaths may depend on the release of
toxic factors (e.g. TNF-a, nitric oxide) produced by activated
macrophages (Bitsch et al., 2000; Hofman et al., 1989; Selmaj et al.,
1991), or by humoral immunity (Genain et al., 1999; Lucchinetti
et al., 2000). The role of serum autoantibodies has gained much
attention in MS research and there are clear therapeutic
repercussions in selected groups of patients. It has been described
that one third of MS patients develop autoantibodies; of note, these
autoantibodies are more frequently detected in RR MS cases (acute
steroid resistant relapses) than in PP MS patients (Elliott et al.,
2012). Moreover, it has been described that lesional pattern II MS
patients are more likely to respond favorably to plasma exchange
as compared to lesional patterns I or III (Keegan et al., 2005). The
antigen speciﬁcity of these autoantibodies has yet to be
established. One of the most promising candidates in MS was
the MOG (Genain et al., 1999). Anti-MOG antibodies have been
described in MS lesions (Genain et al., 1999) and elevated antibody
titers against MOG were also reported in the serum and CSF of MS
patients (Reindl et al., 1999). However, it is now clear that MOG-
speciﬁc autoantibodies are common to a series of human
demyelinating disorders, including pediatric cases of MS, acute
disseminated encephalomyelitis (ADEM), optic neuritis (Willison
and Linington, 2012) and may even be present within healthy
controls (Lampasona et al., 2004). The lack of speciﬁcity of anti-
MOG antibodies has recently been balanced by a report indicating
that the MOG index, which indicates the level of antibodies to MOG
within the CNS, does seem to be a promising diagnostic tool and a
marker of disease progression (Klawiter et al., 2010).
Recently, heteromeric complexes containing the myelin-
derived lipids sulfatides have been identiﬁed as prominent targets
of oligoclonal band antibodies in MS (Brennan et al., 2011). The use
of a ‘combinatorial glycomic’ approach to study glycolipid and lipid
complexes has permitted the isolation of molecular structures
capable of mimicking the in vivo antigenicity of the putative
targets of MS oligoclonal bands (Galban-Horcajo et al., 2014;
Rinaldi et al., 2012). As a result of this (and other) elegant work,
novel autoantibody targets in MS are likely to emerge.
The primary death of oligodendrocytes is a hallmark of type III
and IV lesional patterns, but it is also common in other forms of
oligodendrocytic damage. For example such lesional pathology has
been noted in virus-induced inﬂammatory demyelination
(Itoyama et al., 1982) and in early CNS lesions secondary to an
ischemic/hypoxic mechanisms of injury (Aboul-Enein et al., 2003;
Ludwin and Johnson, 1981). While the type IV pattern is very rare
(the most probable mechanism of action driving this degenerative
pattern is the release of toxic factors by activated macrophages)
(Lucchinetti et al., 2000), demyelination in the type III pattern
seems to be linked to a failure in mitochondrial activity that causes
the death of oligodendrocytes (e.g. via the release of pro-apoptotic
factors), while concurrently disrupting the differentiation of
oligodendrocytes precursor cells (OPCs) (Ziabreva et al., 2010).
The mitochondrial proteins that are likely most affected in these
lesions are cytochrome C oxidase-I, which is essential for the
activity of the mitochondrial respiratory chain complex IV, and the
cytochrome C oxidase-IV, which is important for the assembly and
the stability of complex IV (Mahad et al., 2008). Mitochondrial
injury can be triggered by reactive oxygen species and nitric oxide,
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oxidase 2 burst (Fischer et al., 2012). Enhanced levels of key
subunits of NADPH oxidase type 2 (gb91phox, p22phox) are
observed in the activated microglia of these lesions, thus indicating
the assembly of a functional NADPH oxidase 2 complex (Fischer
et al., 2012). Type III pattern lesions are also characterized by a
reduced number of differentiated macrophages expressing CC
chemokine receptor (CCR)-5 and by an increased number of
undifferentiated macrophages expressing CCR1 (Mahad et al.,
2004), which both support hypoxia-dependent demyelination. In
fact, the transcription factor hypoxia-inducible factor 1-a has been
found in MS type III lesions and it is likely to bind regulatory
elements that increase CCR1 expression (Aboul-Enein et al., 2003;
Scotton et al., 2001).
Understanding the mechanisms that drive demyelination in
different pathological settings is fundamental to the development
of targeted therapies for each patient in each stage of disease.
3.2. Neurodegeneration
While the immune-mediated destruction of CNS myelin and
oligodendrocytes have traditionally been considered the primary
pathologic drivers of MS, progressive GM damage is now
considered to be one of the major causes of irreversible
neurological disability in MS patients. Cortical damage in MS
can occur via an indirect route, which is driven by neuronal loss
induced by retrograde degeneration from WM lesions, or as a
direct consequence of the localization of demyelinated plaques
within the cortex.
Early descriptions of MS pathology emphasized the functional
importance of axonal destruction induced by inﬂammatory WM
lesions, which in turn led to secondary (Wallerian) tract
degeneration and global brain atrophy (Kornek and Lassmann,
1999). It has been described that the formation of new cortical
lesions is more likely to occur in cortical areas that were
previously connected with sites of previous damage in the WM
(Kolasinski et al., 2012), and axonal degeneration has been
identiﬁed as the major determinant of irreversible neurological
disability in the progressive phase of MS. While this process may
remain clinically silent for many years, irreversible neurological
disability ensues as compensatory CNS resources are exhausted
and neurodegenerative mechanisms triggered (Bjartmar et al.,
2003). Understanding the mechanisms that mediate axonal loss in
MS is therefore fundamental to unraveling pathways of disease
progression.
Oligodendrocytes provide axonal insulation and trophic
support that are essential for long-term axonal survival (Nave,
2010). Following demyelination, Na+ channels that are normally
located at the nodes of Ranvier become diffusely distributed along
the axolemma. In conditions of reduced axoplasmic ATP produc-
tion (similar to those present in inﬂammatory WM lesions), the
Na+/K+ ATPase pump that normally exchanges Na+ for extracellu-
lar K+ after depolarization is impaired. In its place the Na+/Ca++
exchanger, which exchanges axoplasmic Ca++ for extracellular
Na+, will reverse its activity leading to axonal increase of Ca++ and
subsequently Ca++ mediated degenerative responses (Smith,
2007; Waxman, 2006). Excessive axoplasmic Ca++ accumulation
causes a vicious cycle of impaired mitochondrial function,
reduced energy production and compromised axonal transport
that further propagates damage (Mahad et al., 2008). This
imbalance between increased energy demand and decreased
energy supply has been termed virtual hypoxia and eventually
leads to degeneration of the axon in the WM (Lassmann, 2003;
Trapp and Stys, 2009).
Formation of axonal ovoids is a pathologic hallmark of
transected axons, which is normally accompanied by a dramaticincrease in non-phosphorylated neuroﬁlament epitopes (Trapp
et al., 1998) and axonal accumulation of amyloid precursor protein
(Ferguson et al., 1997). In acute MS lesions, the terminal axonal
ovoids are often surrounded by macrophages and activated
microglia that release a plethora of substances, including
proteolytic enzymes, cytokines, oxidative products and free
radicals, which can further damage axons (Nave and Trapp,
2008). Activated immune cells and astrocytes are also a major
sources of glutamate in acute MS lesions and can damage
oligodendrocytes, myelin and axons (Matute et al., 2001) by
activating their ionotropic and metabotropic receptors (Geurts
et al., 2003).
Histopathological studies have shown that cortical demyelin-
ation can occur without any obvious anatomical relationships to
diffuse or focal WM changes (Bo et al., 2007). Microarray studies
performed on the cortical tissue of MS patients shed light on the
potential mechanisms underlying the direct damage of cortical
neurons. A study on samples of non-demyelinated cortex revealed
that nuclear-encoded mitochondrial genes, and the functional
activities of the mitochondrial respiratory chain complexes I and
III, were decreased in MS patients (Dutta et al., 2006). Consistently,
a recent gene expression study on actively demyelinating subpial
cortical lesions supported the idea that oxidative injury may be one
of the major driving forces of cortical demyelination (Fischer et al.,
2013). Interestingly, more than 80% of the identiﬁed MS-speciﬁc
genes were related to T cell-mediated inﬂammation, microglia
activation and oxidative injury, thus suggesting strong relation-
ships among these processes.
The profound oxidative injury observed in MS lesions seems to
be related to mitochondrial impairment in damaged axons
(Murphy, 2009). This mitochondrial dysfunction is probably
caused by free oxygen radicals, which are produced during
inﬂammation in the WM but also via the dysfunctional mitochon-
dria themselves (Fischer et al., 2012). This mechanism is ampliﬁed
by the massive liberation of iron from oligodendrocytes and
neurons (Hametner et al., 2013) and the expression of NADPH
oxidase in microglia, as has been previously described (Fischer
et al., 2012). Changes related to mitochondrial function are also
found to be associated with an alteration of genes related to axonal
transport and synaptic function, thus suggesting a relationship
between reduced metabolism and reduced innervation (Dutta
et al., 2011). Consistently, synaptic loss is a characteristic feature of
GM lesions (particularly in type I lesions) (Wegner et al., 2006), and
neurite density is proportionally reduced with increased menin-
geal inﬂammation (Choi et al., 2012).
Whether these mechanisms are a deleterious consequence of
the inﬂammatory disease or whether they are part of a
neuroprotective response of cortical neurons has yet to be clariﬁed
(Dutta and Trapp, 2011). It is plausible to think that a combination
of both indirect and direct causes, serve to induce cortical
degeneration and ultimately GM pathology. A unifying hypothesis
suggests that distant WM inﬂammation can induce a retrograde
neurodegeneration that leads to microglia activation within the
cortex (Lassmann, 2012; Perry et al., 2010). These pre-activated
microglial cells are more easily converted into a cytotoxic
phenotype when exposed to pro-inﬂammatory molecules and
start to release mediators (e.g. reactive oxygen species or nitric
oxide) that favor the imbalance between energy demand and
energy supply in chronically demyelinated axons.
4. Mechanisms of tissue repair and regeneration
4.1. Remyelination
Spontaneous remyelination is a process in which oligoden-
drocytes and OPCs attempt to re-ensheath demyelinated axons
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process that requires multiple steps to be efﬁciently completed
and, as such, the failure of remyelination is a common ﬁnding in
MS pathology.
In the early stages of the illness, remyelination occurs in MS
lesions via repeated cycles of de- and re-myelination, which in turn
lead to a myelin sheath that is both thinner/shorter than normal
(Ludwin and Maitland, 1984). These early remyelinating lesions
are characterized by a signiﬁcant increase in the number of
oligodendrocyte transcription factor (Olig)2+ OPCs (Kuhlmann
et al., 2008), which are distributed along an increasing gradient
from the core to the periphery of the lesion (Kuhlmann et al., 2008;
Moll et al., 2013). Although it has been shown that the majority of
these lesions display a very low number of mature oligodendro-
cytes after damage (Lucchinetti et al., 1999), a certain degree of
remyelination does occur in early MS lesions and up to a third of
the OPCs transition to NogoA+ mature oligodendrocytes in vivo
(Kuhlmann et al., 2008). Post-mortem studies have also come to
suggest that the extent of remyelination is in part related to the
location of the lesions, as deep WM and subcortical lesions are
more likely to be completely remyelinated than those lesions
localized in proximity of the periventricular areas (Patrikios et al.,
2006).
In chronic MS, the limited capacity for spontaneous remye-
lination is even more pronounced (Antel et al., 2012). Maturing
OPCs are rarely present in chronic MS lesions of the WM, thus
suggesting a block in the differentiation of OPCs as the major
determinant of remyelination failure. The reasons behind this
progressive reduction of remyelinating ability throughout the
disease course are not fully understood. However, it is reasonable
to speculate that the altered and less efﬁcient inﬂammatory
responses in chronic MS might be the cause of the witnessed
different extent of remyelination (Kuhlmann et al., 2008). In fact,
the previously described slowly expanding lesions (characteristic
of progressive MS) may be linked to impaired clearance of myelin
debris, which constitute inhibitory cues serving to disrupt
remyelination in the chronic phases of the disease process
(Bramow et al., 2010; Miron and Franklin, 2014). Despite the
critical role played by inﬂammation in the pathogenesis of the
disease, it appears that one of the main determinants for proﬁcient
remyelination and enhancement of reparative processes in the
WM is in fact the effective activation of the immune system
(Peruzzotti-Jametti et al., 2014). Of note, failure of remyelination
within the GM is likely to be at least in part, due to other
mechanisms. For example, post-mortem studies on patients with
progressive MS have revealed that the density of OPCs and pre-
myelinating oligodendrocytes is not decreased in cortical lesions
(Chang et al., 2002), and this is likely due to a more permissive
microenvironment for OPCs within the cortex (e.g. less extracel-
lular matrix molecules and less astrogliosis), as later described
(Chang et al., 2012).
On a cellular/molecular level, failure in myelin repair is linked
to (i) inadequate activation, (ii) inefﬁcient recruitment and/or (iii)
lack of differentiation of OPCs (Franklin and Gallo, 2014). While
OPC activation relies on the re-expression of certain developmen-
tal genes (e.g. the transcription factors Olig1 or Olig2) that are
expressed during early myelinogenesis (Arnett et al., 2004; Kim
et al., 2011), OPC recruitment is ultimately affected by the presence
of inhibitory cues. Accumulation of the extracellular matrix
glycoprotein anosimin-1 (Clemente et al., 2011), increase in
ﬁbronectin (Stoffels et al., 2013) and hyaluronan (Back et al.,
2005) are all inhibitory for remyelination. In the CSF, soluble
mediators that may affect remyelination, such as antibodies
against the OPC-speciﬁc surface glycoproteins (i.e. AN2), have been
described in MS patients (Niehaus et al., 2000). Within MS lesions
the accumulation of inhibitory chemotaxic molecules may preventthe recruitment of OPCs to the demyelinating site. Overexpression
of the chemorepulsive member of the semaphorin family,
semaphorin 3A has been associated with a failure of OPC
recruitment (Boyd et al., 2013); and similarly, post-mortem MS
studies on chronic lesions showed high expression of the
chemorepulsive molecule netrin-1 to be coupled by reduced
OPC migration and differentiation (Tepavcevic et al., 2014).
OPC differentiation is composed of three different steps: (i)
OPCs establish contact with an axon, (ii) they express a series of
myelin-speciﬁc genes, and (iii) they ensheath the axon. All of these
mechanisms are tightly regulated by the release of several of
growth factors (e.g. ﬁbroblast growth factor-2 and platelet-derived
growth factor) (Murtie et al., 2005) and by the activation of speciﬁc
membrane/nuclear signaling pathways. The expression of the
transcription factor Sox17 is increased in active WM MS lesions,
where it promotes OPC cell cycle exit and differentiation (Moll
et al., 2013; Sohn et al., 2006). Similarly, Ascl-1 expression is
increased at the active border of MS lesions, and guides OPC
differentiation (Nakatani et al., 2013). Interestingly, the retinoid X
receptor g (RXRg), a member of the nuclear receptor superfamily
that mediates signaling by 9-cis retinoic acid (a vitamin A
derivative), has been shown to drive oligodendrocyte differentia-
tion and myelin sheath formation by OPCs (Huang and Franklin,
2012; Huang et al., 2011a,b). Being that RXRg is highly expressed
in acute and remyelinating lesions, RXR agonists have been
explored in the pathophysiologic context of MS and shown to
improve remyelination in both an ex vivo culture system and in
EAE animal models (Diab et al., 2004). Clinical trials evaluating RXR
agonists for chronic MS are anticipated as a licensed RXR agonist,
bexarotene, is already in clinical use for the treatment of cutaneous
T cell lymphoma (Rodgers et al., 2013).
4.2. Cortical regeneration
A number of adaptive mechanisms delay (or compensate) for
the neuronal degeneration in MS patients. Several functional
MRI studies have identiﬁed the diffuse activation of cortical
areas as a mechanism aimed at overcoming functional loss
induced by MS lesions (Rocca et al., 2005). On a cellular level,
neurogenesis can occur in chronic MS lesions (Chang et al.,
2008) and remyelination by OPCs may account for the majority
of tissue restoration (Franklin et al., 1997). Interestingly, post-
mortem studies on patients with progressive MS, have disclosed
that remyelination is more pronounced in cortical lesions than
in WM lesions. This is likely due to a more permissive
environment within the cortex (i.e. less extracellular matrix
molecules and less astrogliosis) for remyelination, which leads
to an enhanced recruitment of OPCs.
As for WM lesions, the immune system plays a pivotal role in
GM regeneration. The presence of microglia/macrophages in
every step of the evolving GM lesion suggests a role for
mononuclear cells in clearing the environment of growth
inhibitory molecules (Piccio et al., 2007; Takahashi et al., 2007).
Microglia/macrophages can indeed shape the environment by
directly secreting local neurotrophic factors (e.g. brain-derived
neurotrophic factor, nerve growth factor, neurotrophin-3 and
oncomodulin) and indirectly stimulating (via IL-1b) local CNTF
production (Martino, 2004; Rawji and Yong, 2013). Interestingly,
when transcriptional and translational products of CNTF-related
genes were quantiﬁed in MS cortices (CNTF, CNTF receptor and
downstream CNTF signaling molecules), they were found to be
markedly increased in the neurons of MS patients (Dutta et al.,
2007). Higher levels of CNTF were also found in the CSF of MS
patients recovering from acute exacerbations (Massaro et al.,
1997), thus suggesting its crucial role in both endogenous defense
and regenerative mechanisms.
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5.1. Approved immune-modulatory treatments
The current US Food and Drug administration (FDA) and
European Medicines Agency (EMA) approved treatments for MS
primarily target the underlying immunologic etiology of the
disease. Approved MS-speciﬁc disease modifying treatments
include injectable therapies [interferon-b (IFN-b) and glatiramer
acetate], oral therapies (teriﬂunomide, dimethyl fumarate, and
ﬁngolimod), and infusion therapies (mitoxantrone, natalizumab
and alemtuzumab). The detailed effects and mechanisms of action
of these drugs are summarized in Table 2.
The proximate aimof MS therapy is the reduction of clinical
relapses and the decreased accumulation of nascent MRI lesions,
while the overarching goal of MS therapy is to delay the evolution
from a relapsing phenotype to that of a progressive phenotype. To
fulﬁll these aims, a two-fold strategy has been widely adopted by
physicians, which centers on the short-term treatment with
glucocorticoids (i.e. to reduce the accumulation of disease burden
after a relapse), and the long-term treatment with disease-
modifying drugs (DMDs), which prevent relapses and while
possibly hindering MS progression.
5.1.1. Glucocorticoids
Glucocorticoids have short-term effects on the speed of
functional recovery in patients with acute attacks of MS and are
thus used in the treatment of acute exacerbations in RR MS
patients (Berkovich, 2013). Glucocorticoids display a variety of
immune modulatory mechanisms of action including, the inhibi-
tion of antigen presentation, anti-inﬂammatory effects (e.g.
reduction of edema and arachidonic acid metabolites), a decrease
in pro-inﬂammatory cytokine expression and the inhibition of
lymphocyte proliferation (Sloka and Stefanelli, 2005). Typically,
they are administered at high doses intravenously during relapse
periods, without tapering post-therapy. Interestingly, a 2013 trial
with a small number of patients reported that administration of
bioequivalent doses of oral methylprednisolone was not inferior to
intravenous methylprednisolone in terms of both the safety and
efﬁcacy proﬁles, measured via clinical disability and MRI activity
four weeks after MS relapse (Ramo-Tello et al., 2014). However,
before extension to clinical practice, these promising results must
be conﬁrmed in larger cohorts and with a more vigorous period of
follow-up. Of note, long-term glucocorticoid treatment has not
been proven to exert beneﬁcial effects on the progressive stages of
MS (Ciccone et al., 2008). Additionally, the extended use of
glucocorticoids carries an adverse proﬁle of side effects, which can
include osteoporosis, metabolic syndrome, stomach ulcers, catar-
acts, and muscle weakness (Sloka and Stefanelli, 2005). Therefore,
DMDs currently remain the most appealing and therapeutically
efﬁcacious drugs for the long-term treatment of RR MS patients.
5.1.2. Disease-modifying drugs
Options for long-term treatment of MS have undergone a rapid
expansion over the last few years. In a simpliﬁed scenario,
approved long-term MS therapy can now be grouped into four
major categories, which depend on their presumed targets and
mechanism of actions: immunomodulators (IFN-b, glatiramer
acetate and dimethyl fumarate), inhibitors of immune cell
trafﬁcking (natalizumab and ﬁngolimod), inhibitors of cell
replication (teriﬂunomide, mitoxantrone), and those that promote
immune cell depletion (alemtuzumab).
Three preparations of IFN-b have been approved by the US FDA
and have been shown to decrease clinical relapse rate and to
reduce the development of new active brain lesions in RR MS
(Interferon, 1995; Randomised, 1998; Jacobs et al., 1996). Of note,one of those preparations (the IFN-b 1b) is also licensed for the
treatment of SP MS patients (1998). The exact mechanisms
underlying the beneﬁcial effects of IFN-b are likely based on the
immune modulatory properties of the molecule, which include the
antagonism of IFN-g-mediated MHC up-regulation on APCs, the
shift of cytokine expression to an anti-inﬂammatory proﬁle, and
the modulation of apoptosis. IFN-b may also block the migration of
T cells across the endothelium and inhibit T cell activation (Dhib-
Jalbut and Marks, 2010; Kieseier, 2011). Adverse events of IFN-b
include injection-site reactions, ﬂu-like symptoms, leukopenia,
deranged liver enzymes, and dysthyroidism.
Glatiramer acetate is a random polymer of glutamic acid, lysine,
alanine and tyrosine licensed for the treatment of RR MS patients
(Johnson et al., 1995). The exact mechanisms of action remain
unknown but may be dependent on the induction of antigen-
speciﬁc suppressor T cells, the inhibition of antigen presentation,
the shift to an anti-inﬂammatory phenotype of the CD4+ T cell
population, and/or the inhibition of myelin basic protein binding to
the T cell receptor (Racke et al., 2010). Adverse events include local
injection-site reactions, transient systemic post-injection reac-
tions (i.e. chest pain, ﬂushing, dyspnea, palpitations, and/or
anxiety) and lipodystrophy (with long-term therapy).
Dimethyl fumarate (a methyl ester of fumaric acid) is an
immunomodulatory agent approved for the treatment of RR MS
(Fox et al., 2012a; Gold et al., 2012), that promotes a shift in
cytokine production from a pro-inﬂammatory Th1-like pattern to
an anti-inﬂammatory Th2 pattern, and down-regulates CNS
oxidative stress by activating the nuclear factor (erythroid-derived
2)-related factor-2, a transcription factor with antioxidant
properties (Albrecht et al., 2012; Scannevin et al., 2012). The most
common side effects of dimethyl fumarate are ﬂushing and
gastrointestinal symptoms. Although fumaric acid has been long
licensed for the treatment of psoriasis, progressive multifocal
leukoencephalopathy (PML), a rare potentially fatal neurologic
disease caused by reactivation of JC virus infection, has been
reported in rare cases (Ermis et al., 2013; van Oosten et al., 2013).
Natalizumab is a recombinant humanized monoclonal antibody
that is licensed for the treatment of RR MS (Polman et al., 2006b;
Radue et al., 2010), and is currently under investigation for the
treatment of progressive MS (ClinicalTrials.gov Identiﬁer:
NCT01077466 and NCT01416181). Via the blocking of a4-integrin
binding to VCAM-1, natalizumab prevents the adhesion of
leukocytes to the endothelium and their subsequent migration
into the CNS (Lutterotti and Martin, 2008). This treatment is aimed
at restoring (or stabilizing) the BBB by creating a normal proﬁle of
cytokine expression and blocking the transendothelial migration
of activated lymphocytes (Minagar and Alexander, 2003). Nata-
lizumab has beneﬁcial effects on relapse rate and MRI lesion
activity. Further, it has been shown to slow the progression of
disability, yet it carries the risk of allergic reactions, liver toxicity,
headache, fatigue and the development of PML (Langer-Gould
et al., 2005). The risk of PML is increased by (i) the duration of
natalizumab therapy, (ii) prior immunosuppressant treatment,
and (iii) positive status with respect to anti-JC virus antibodies
(Bloomgren et al., 2012).
Fingolimod is a structural analog of sphingosine, and targets
sphingosine 1-phosphate receptors type 1,2,3 and 5. This molecule
inhibits the sphingosine 1-phosphate signaling and strongly
modulates the immune system by hindering the migration of
lymphocytes from secondary lymphoid organs to the CNS,
resulting in a marked decrease in the peripheral circulation and
their reduced recruitment to sites of inﬂammation (Cohen et al.,
2010). Fingolimod is approved for RR MS (Cohen et al., 2010;
Kappos et al., 2010), and its efﬁcacy in PP MS is currently being
investigated (ClinicalTrials.gov Identiﬁer: NCT00731692). The use
of ﬁngolimod is associated with bradycardia and atrioventricular
Table 2
Disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis.
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infections, elevated liver enzymes and macular edema (Jain and
Bhatti, 2012).
Teriﬂunomide is an active metabolite of leﬂunomide, approved
for the treatment of RR MS (Confavreux et al., 2014; O’Connor et al.,
2011; Vermersch et al., 2014). The precise mechanisms of action
are not completely understood. However, it has been shown that
teriﬂunomide inhibits mitochondrial dihydroorotate dehydroge-
nase, which reduces the de novo synthesis of pyrimidine
nucleotides in proliferating cells. Through dihydroorotate dehy-
drogenase-independent mechanisms, such as the inhibition of
phosphorylation of protein kinases, teriﬂunomide promotes an
anti-inﬂammatory cytokine milieu and inhibits the interaction
between APCs and T cells (Claussen and Korn, 2012). The most
common adverse effects of teriﬂunomide are diarrhea, nausea,
alopecia, hair thinning, and elevated alanine aminotransferase
levels.
Mitoxantrone is an anthracenedione that affects DNA topo-
isomerase II, leading to an impairment of T and B cell proliferation
(Vollmer et al., 2010). Currently, mitoxantrone is restricted to
highly active patients who have failed second line treatments
(lifetime cumulative dose is <140 mg/m2) (Martinelli Boneschi
et al., 2005). However, due to the high risk of leukemia (1% of
treated patients) (Chan and Lo-Coco, 2013; Marriott et al., 2010;
Martinelli et al., 2011) and of cardiotoxicity, its use in clinical
practice has been progressively abandoned in favor of novel
treatments, which have better therapeutic index (e.g. natalizumab,
alemtuzumab).
Alemtuzumab is a humanized monoclonal antibody directed
against CD52, a surface glycoprotein present on a number of mature
leukocyte subpopulations, including T, B, and NK cells (Investiga-
tors et al., 2008). Binding of alemtuzumab to CD52 results in a
profound complement- and antibody-dependent cellular cytotox-
icity, which is followed by leukocyte reconstitution that temporally
varies between leukocyte subpopulations (e.g. B cell numbers
recover in approximately 6 months, whereas T cells require more
than 1 year). Alemtuzumab has been recently licensed for the
treatment of RR MS by the FDA and when compared to IFN-b 1a, has
shown great efﬁcacy in reducing relapse rates, disability and MRI
activity (Tuohy et al., 2015; Cohen et al., 2012; Coles et al., 2012;
Investigators et al., 2008). Adverse events associated with the use of
alemtuzumab are hyperacute cytokine release syndrome and the
development of autoimmune diseases (i.e. Graves disease, idio-
pathic thrombocytopenic purpura and Goodpasture syndrome)
(Clatworthy et al., 2008; Jones et al., 2009).
Currently two different strategies with regard to the long-term
treatment of MS patients with DMDs have been adopted.
Escalation strategy is centered on a rational therapeutic approach,
in which drugs with the greatest therapeutic index (i.e. best risk–
beneﬁt ratio) are ﬁrst line. If needed, drugs which are more
powerful (but typically more toxic) are successively adopted
(Rieckmann, 2009). Induction therapy represents a more aggres-
sive therapeutic approach and depends instead on the use of
powerful immunosuppressant drugs from the beginning (i.e. an
attempt to reset the immune system) (Rieckmann, 2009).
Generally speaking, patients who suffer from non-aggressive
forms of RR MS are good candidates for escalation strategy,
whereas those who suffer from aggressive forms of RR MS are more
likely to be placed on an induction centered management strategy.
5.1.3. Autologous hematopoietic stem cell transplantation
The transplantation of hematopoietic stem cells (HSCs) is a
widely used therapy for patients with hematopoietic malignancies
and solid tumors. Autologous HSC transplantation has also been
successfully used to suppress aberrant immune function in many
autoimmune diseases (e.g. lupus, rheumatoid arthritis, and type
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from the patient’s bone marrow after mobilization into the
circulation and collected using leukapheresis. Non-myeloablative
chemotherapy and immune-depleting biological agents are then
administered to ablate the autoreactive immune system. Eventu-
ally, the immune system is renewed via the infusion of previously
isolated, autologous HSCs (Atkins and Freedman, 2013).
It is believed that HSC transplantation is more likely to be
effective for patients with an aggressive form of MS (i.e. with
profound CNS inﬂammation and severe clinical disability), by
controlling the inﬂammatory response and reducing clinical
relapses. In fact, following HSC transplantation in patients with
aggressive SP MS, a dramatic stabilization and/or improvement of
the neurological condition has been observed over a follow-up
period of four years (Fagius et al., 2009; Kimiskidis et al., 2008;
Mancardi et al., 2005). Of note, HSC transplantation in non-
aggressive SP MS patients only induced mild clinical improve-
ments (Chen et al., 2012; Shevchenko et al., 2012).
5.2. Novel perspectives
5.2.1. Immune-modulatory therapies for progressive MS
DMDs have transformed the pharmaceutical landscape and the
burden of disease associated with deﬁned subtypes of MS (i.e. RR
MS). Unfortunately, such meaningful advances are still lacking for
those suffering from progressive forms of the disease. While it has
become increasingly clear that DMDs are effective at reducing
relapses mediated by the activation of T cells, they seem to have
negligible effects on the primary mechanisms governing progres-
sive tissue damage (e.g. failure of remyelination, neurodegenera-
tion and persistent microglia/macrophage activation). As such, the
results obtained from the latest phase III clinical trials with
interferons (Leary et al., 2003), glatiramer acetate (Wolinsky et al.,
2007), and rituximab (Hawker et al., 2009) in PP MS have yielded
negative results. In line with the aforesaid, novel therapeutic
approaches that interfere with the other cells of the immune
system (e.g. B cells) that drive disease progression are currently
undergoing clinical development.
It has been described that a single intravenous course of
rituximab is capable of reducing inﬂammatory brain lesions and
clinical relapses for 48 weeks in RR MS patients (Hauser et al.,
2008). This initial observation provided deﬁnitive evidence of B-
cell involvement in the pathophysiology of MS and has prompted
the use of rituximab in SP MS patients as well. The ongoing
RIVITaLISe trial is now testing the intravenous and intrathecal
injections of rituximab in patients with SP MS (NCT01212094). The
intrathecal route of administration of rituximab was chosen in an
effort to target what has become increasingly recognized as
compartmentalized CNS inﬂammation. Such focused inﬂammation
within the context of an intact BBB (e.g. tertiary lymphoid
structures) is indeed one of the major drivers of progression in
chronic MS.
5.2.2. Regenerative and neurotrophic molecules
Promising new strategies have been shown to speciﬁcally
target the failure of remyelination and the neurodegeneration
typical of MS. One promising candidate is anti-LINGO-1 mono-
clonal antibody (BIIB033). Oligodendrocytes and neurons express
LINGO-1, which regulates OPC differentiation and remyelination.
MS lesions express an increased level of LINGO-1 and it has been
shown that LINGO -1 antagonism enhances remyelination (Mi
et al., 2013). Two separate randomized, placebo-controlled phase I
studies with the BIIB033 vs. placebo (administered via intrave-
nous infusion to 64 healthy adult volunteers and 42 subjects
with RR MS or SP MS) were conducted (Tran et al., 2012).
BIIB033 exhibited a favorable safety proﬁle, and a desirablepharmacokinetics and pharmacodynamics. These ﬁndings
prompted the start of a phase II clinical trial with BIIB033 (used
concurrently with interferons), which is currently ongoing in
patients with RR MS (ClinicalTrials.gov identiﬁer: NCT01864148).
A second promising therapy is riluzole, which inhibits the
glutamatergic activity by blocking the release of glutamate and
aspartate, thereby altering the function of glutamate receptors and
sodium channels (Wokke, 1996; De Jager and Haﬂer, 2007).
Unfortunately, a phase II clinical trial on the effect of riluzole
(added to weekly intramuscular IFN-b 1a) vs. placebo in early MS
provided evidence that riluzole treatment does not meaningfully
reduce brain atrophy in early MS (Waubant et al., 2014). However,
a phase II clinical trial on 15 patients with PP MS showed that
riluzole can reduce the rate of cervical cord atrophy and the
development of hypointense T1 brain lesions on MRI (Kalkers et al.,
2002). Additional studies are required to unravel the therapeutic
potential of these therapies for MS patients.
5.2.3. Cellular therapies
While it is not the aim of this review to cover drugs which are in
the pre-clinical stages of development, it is nonetheless important
to highlight critical pre-clinical research on MS that has led to
several promising approaches shown to potentiate mechanisms of
tissue recovery (Deshmukh et al., 2013; Mangas et al., 2010;
Munzel and Williams, 2013; Van der Walt et al., 2010). Among
these, stem cells possess a therapeutic potential that is distinct
from that of small molecules and biologics. Part drug and part
device, stem cells work as naturally-occurring DMDs that sense
diverse signals, migrate to speciﬁc sites in the body, integrate
inputs to make decisions, and execute complex response
behaviors, all in the context of speciﬁc tissue microenvironments
(Fischbach et al., 2013). All these attributes may be harnessed to
treat a number of disease processes, including the persistent
inﬂammation and tissue degeneration that occur in progressive
MS.
However, before envisaging any potential human applications
of such innovative therapies, we need to confront relevant
challenges that include the identiﬁcation of an ideal stem cell
source for downstream transplantation.
Due to their availability and potentially beneﬁcial properties,
mesenchymal stem cells (MSCs) have been at the forefront of
reparative/regenerative medicine for several diseases, including
MS. In progressive MS, intravenous autologous MSC transplanta-
tion was successfully carried out in an open-label phase 2 study
(Connick et al., 2012). Ten progressive MS patients were treated
with a single intravenous administration of autologous bone-
marrow-derived MSCs without causing serious adverse events.
Beyond their safety, autologous MSCs were shown to induce an
improvement in some visual endpoints that were structural (i.e.
optic nerve area), functional (i.e. visual acuity) and physiological
(i.e. visual evoked response latency) in nature. The neuroprotective
effects of MSCs seems to be independent of directed differentiation
and/or cell replacement, but rather rely on mechanisms of
peripheral immunomodulation.
Of note, the use of intrathecally delivered autologous MSCs in
MS has also been adopted. Although three recent reports show that
intrathecally delivered MSCs are relatively safe (Karussis et al.,
2010; Mohyeddin Bonab et al., 2007; Yamout et al., 2010), the
authors speculate that there is a risk of treatment-related
malignant neoplasm induction (Rosland et al., 2009). While
important advances have been made with regard to the use of
MSCs in MS, substantial challenges remain and include the nature,
identity, function, mode of isolation and experimental handling of
MSCs (Bianco et al., 2013).
In diseases of the CNS in which stem cell-mediated effects (i.e.
bystander and tissue replacement) are desirable, the use of tissue
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have been shown to exert remarkable trophic effects on endoge-
nous brain cells, including endogenous myelin forming cells, and
beneﬁcial modulatory actions on innate and adaptive immune
responses in mouse (Pluchino et al., 2005) and non-human
primates models of MS (Martino et al., 2011; Pluchino and
Cossetti, 2013; Pluchino et al., 2009).
Several phase I and II trials have been undertaken for the use of
NSCs (derived from fetal allogeneic sources) in incurable CNS
diseases (e.g. amyotrophic lateral sclerosis, stroke, Pelizaeus-
Merzbacher disease, Batten’s disease), but clinical trials for MS are
still lacking (Chiu and Rao, 2011). Major limitations associated
with the use of somatic NSCs therapies for human diseases include
the source from which somatic NSCs are derived (either fetal or
embryonic), the immunogenicity of the derived allogeneic graft,
and the limited expandability/genotypic stability over extensive
passaging in vitro. As such, risks of transplant rejection (Fox et al.,
2012b; Pearl et al., 2012), and key ethical controversies (Ramos-
Zuniga et al., 2012) have prevented the translation of NSC therapy
into the clinic.
The generation of induced pluripotent stem cells (iPSCs) from
adult skin ﬁbroblasts has heralded the possibility of autologous
transplants that would circumvent histocompatibility barriers.
iPSCs are pluripotent stem cells with molecular and functional
properties similar to embryonic stem cells that can be isolated
from the very same patient and differentiated toward multipotent
tissue speciﬁc cells. While iPSC technology displays tremendous
promise with regard to regenerative medicine, the ﬁeld of cellular
reprogramming is one that is still developing. As such, the de-
differentiation of somatic cells into pluripotent cells comes with an
intrinsic set of limitations. These include major difﬁculties in
obtaining differentiation into speciﬁc lineages and the require-
ment of extensive passaging in vitro (Fong et al., 2010). Further,
one cannot exclude the possibility of remaining neoplastic
pluripotent cells in the ﬁnal medical product (Liang and Zhang,
2013).
Advances in the direct conversion (transdifferentiation) of
somatic cells into multipotent/stably expandable induced NSCs
(iNSCs) may overcome histocompatibility barriers and avoid
extensive in vitro manipulation (Thier et al., 2012). The iNSCs
obtained from skin ﬁbroblasts are stably expandable, tissue
speciﬁc, display unlimited self-renewal and can be differentiated
in vitro giving rise to multiple subtypes of neurons, astrocytes and
oligodendrocytes. Compared with the circuitous two-step strategy
used during the conversion of somatic cells to iPSCs (and
subsequent differentiation into neural stem cells), the relatively
straightforward reprogramming of iNSCs is highly efﬁcient, direct
and safe. While the generation of human iNSCs has been already
achieved, future experiments will be necessary to help deﬁne the
potential of these cells in the context of immunomodulation and/or
tissue trophism inMS.
Of note, a recent open-label, phase I clinical trial designed to
evaluate the safety and tolerability of intrathecal administration of
autologous MSCs-derived NSCs could represent a groundbreaking
approach to the treatment of progressive MS (NCT01933802).
These MSCs-derived NSCs display a reduced expression of
mesodermal markers and reduced capacity for adipogenic or
osteogenic differentiation that may reduce the potential of
unwanted mesodermal differentiation upon CNS transplantation
(Harris et al., 2012), while concurrently maintaining many of the
advantages displayed by both MSCs and NSCs.
6. Conclusions
Recent scientiﬁc and clinical work has provided key insights
into the pathogenesis of the diverse spectrum of lesions in MSpatients. Although the pathogenesis of MS remains an active area
of investigation, understanding the salient features that drive the
evolution of MS lesions in different brain regions (space) during
diverse disease phases (time), will help to develop future
therapeutic approaches.
Further work is needed to deﬁne what are the exact
immunological and neurobiological mechanisms underlying the
heterogeneous patterns of MS lesional pathology and whether
patients suffering from certain subtypes of disease would require
unique combinations of therapy. Ultimately, a comprehensive
understanding of the deﬁnitive nature, location and cellular make-
up of MS lesions will allow the translation of relevant biological
targets into clinical signiﬁcant therapies for patients in need.
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